The Pittsburgh Life Sciences
Greenhouse (PLSG), the private/public partnership putting the region's life
sciences industry on a fast track for growth, today announced that PLSG has
invested $100,000 in RedPath Integrated Pathology, Inc. The company
provides specialized cancer diagnostic testing that integrates traditional
pathology practice with molecular genetic analysis to improve the diagnosis
of disease.
"RedPath's patented platform approach, PathFinderTG(TM), has made
tremendous advances in the diagnosis of cancer," said Doros Platika, M.D.,
the President and Chief Executive Officer of the PLSG. "The company has
struck the right balance between pathology, molecular analysis and the
information sciences to successfully apply genomic advances in the clinical
setting." Dr. Platika, continued, "In two short years, RedPath has gained
real traction in the marketplace as evidenced by an ever-increasing number
of marquis clients and steady increases in revenues."
RedPath's PathFinderTG is effective at resolving uncertain diagnoses by
answering important questions from pathologists and clinicians when
standard testing is inconclusive. It has been clinically validated for use
in a wide range of specialties, including cancers of the gastrointestinal
tract, pancreas, and brain, and it improves patient outcomes by reducing
the potential for inappropriate, incomplete or unnecessary treatment.
"RedPath's role in changing tissue analysis from a static to dynamic
process has earned us a position within that small but growing class of
molecular-based companies that are pushing healthcare closer to
personalized medicine," said Mary Del Brady, RedPath's President and Chief
Executive Officer. "With the kind of support we have gotten from the PLSG,
we are even more confident that we will be able to achieve a series of key
goals that will help us to maintain our leadership position."
About the Technology Development Fund (TDF)
The Technology Development Fund is a competitive funding program
designed to increase the commercialization potential of life science
technologies developed by the region's scientists and entrepreneurs. The
intent is to provide financial support to verify the technical and
commercial feasibility of early stage inventions that will accelerate and
increase the likelihood that the technology will be successfully
commercialized through a regional start-up company. These funds can be used
in conjunction with or to leverage other early sources of funding.
About RedPath
RedPath Integrated Pathology is a renowned pathology services company
founded in 2004 and dedicated to facilitating superior disease diagnosis.
It is one of the first commercial laboratories to integrate molecular DNA
analysis with traditional pathology, providing early and definitive cancer
diagnosis to pathologists, oncologists and clinicians where it would
otherwise not exist. For further company details, visit redpathip.
About the PLSG
The Pittsburgh Life Sciences Greenhouse is a public/private
partnership, founded by the University of Pittsburgh, Carnegie Mellon
University, UPMC Health System, the Commonwealth of Pennsylvania and its
regional foundation community. Together with private industry and advanced
research and healthcare capabilities of our institutional partners, PLSG
invests in and supports the growth of regional life sciences companies in
the areas of: bioinformatics; bionanotechnology; diagnostics; medical
devices; medical robotics; therapeutics; and tools and services.
Pittsburgh Life Sciences Greenhouse
plsg
redpathip